Context Therapeutics
CNTX
52 hedge funds and large institutions have $76.4M invested in Context Therapeutics in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
24% more funds holding
Funds holding: 42 → 52 (+10)
21.49% more ownership
Funds ownership: 75.58% → 97.06% (+21%)
31% less capital invested
Capital invested by funds: $111M → $76.4M (-$34.7M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$25.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$3.72M |
| 3 |
BOCH
Blue Owl Capital Holdings
New York
|
+$1.64M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.21M |
| 5 |
Renaissance Technologies
New York
|
+$471K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$3.9M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$2.08M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$847K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$529K |
| 5 |
ABG
Ally Bridge Group
New York
|
-$313K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
JP Morgan Chase
New York
| $174 | -$12 | -7 | -4% |
|
|
SS
52
SBI Securities
Tokyo,
Japan
| $119 | +$196 | +113 | New |
|
|
YIH
53
Y-Intercept (HK)
Hong Kong
| – | -$89.4K | -45,635 | Closed |
|
|
JFG
54
Jefferies Financial Group
New York
| – | -$84.7K | -43,200 | Closed |
|
55
Two Sigma Investments
New York
| – | -$27.1K | -13,844 | Closed |
|
|
AF
56
Advisornet Financial
Minnetonka,
Minnesota
| – | -$392 | -200 | Closed |
|
CNTX Hedge Fund Activity: Q4 2024 in Review
52 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q4 2024, worth a combined $76.4M — down 31% from $111M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CNTX positions and 4 closed out — a net gain of 10 holders — while 15 added to existing stakes and 12 trimmed.
The largest buyer was MPM BioImpact, opening a new position worth an estimated $25.4M. The largest seller was Great Point Partners, cutting an estimated $3.9M.
- 52 institutional investors held Context Therapeutics (CNTX) as of Q4 2024, up from 42 in Q3 2024.
- Funds reported $76.4M of Context Therapeutics stock for Q4 2024, down 31% quarter-over-quarter.
- 14 funds opened new Context Therapeutics positions in Q4 2024 and 4 closed out, a net change of +10 holders.
- The largest Context Therapeutics buyer in Q4 2024 was MPM BioImpact, an estimated $25.4M added.
- The largest Context Therapeutics seller in Q4 2024 was Great Point Partners, an estimated $3.9M sold.
Based on aggregated 13F filings for Q4 2024.